Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Nizatidine is a selective H2-receptor antagonist widely utilized in the management of acid-related gastrointestinal disorders. First synthesized by Eli Lilly and Company, it was introduced to the market as an alternative to earlier agents like cimetidine and ranitidine, offering a more favorable safety profile with fewer drug interactions. Its chemical identity is defined by the molecular formula C13H25N3O2S4, corresponding to a CAS registry number of 76098-83-6. Structurally, nizatidine features a thiazole ring and a sulfide bridge, which are critical for its high affinity and specificity toward histamine H2 receptors located on gastric parietal cells.
The primary clinical application of nizatidine involves the treatment of active duodenal ulcers and benign gastric ulcers. By competitively blocking histamine from binding to H2 receptors, it effectively inhibits the secretion of gastric acid, thereby creating an environment conducive to ulcer healing. Furthermore, it is indicated for the maintenance of healed ulcers to prevent recurrence and is used in the management of gastroesophageal reflux disease (GERD) to alleviate symptoms such as heartburn and regurgitation. Unlike some older H2 blockers, nizatidine demonstrates minimal inhibition of cytochrome P450 enzymes, significantly reducing the risk of adverse drug-drug interactions, particularly with medications metabolized by this pathway.
Pharmacokinetically, nizatidine exhibits rapid absorption following oral administration, with peak plasma concentrations reached within one to two hours. It has a relatively short half-life, typically requiring twice-daily dosing for optimal therapeutic effect. The drug is primarily excreted unchanged in the urine, necessitating dose adjustments in patients with severe renal impairment. While generally well-tolerated, common side effects may include headache, dizziness, and gastrointestinal disturbances. Rare instances of hepatic dysfunction or hematological abnormalities have been reported but are uncommon. Due to its efficacy and safety profile, nizatidine remains a valuable option in the therapeutic arsenal for acid-peptic diseases, providing reliable symptom relief and promoting mucosal healing in diverse patient populations.